Research programme: respiratory tract disorder therapeutics - Chiesi Farmaceutici

Drug Profile

Research programme: respiratory tract disorder therapeutics - Chiesi Farmaceutici

Latest Information Update: 28 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chiesi Farmaceutici
  • Class Corticosteroids
  • Mechanism of Action Leucocyte elastase inhibitors; P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Asthma; Bronchiectasis; Bronchopulmonary dysplasia; Chronic obstructive pulmonary disease; Cystic fibrosis

Most Recent Events

  • 28 Dec 2017 Chiesi Farmaceutici plans a phase I/II trial for Asthma and Chronic Obstructive Pulmonary Disease in United Kingdom (NCT03378648)
  • 28 Jun 2016 Preclinical development is ongoing for Asthma, Cystic Fibrosis, Chronic obstructive pulmonary disease and Bronchiectasis in Italy (Chiesi Farmaceutici pipeline, June 2016)
  • 13 Jan 2016 Preclinical trials in Bronchopulmonary dysplasia in Italy (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top